101
|
Ghrenassia E, Avouac J, Derk C, Airo P, Khanna D, Berezne A, Tiev K, Ingegnoli F, Rosato E, Caramaschi P, Hesselstrand R, Riccieri V, Bae S, Steen V, Allanore Y. FRI0242 Watermelon stomach in systemic sclerosis: A EUSTAR case-control study. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.2699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
102
|
Sung J, Yoon M, Chung W, Shin D, Bae S, Kim D. SU-E-T-267: Preliminary Study of Development of the Respiratory Training System by Using the MEMS Acceleration Sensor for the Radiation Therapy. Med Phys 2013. [DOI: 10.1118/1.4814702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
103
|
Hébert-Magee S, Bae S, Varadarajulu S, Ramesh J, Frost AR, Eloubeidi MA, Eltoum IA. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology 2013; 24:159-71. [PMID: 23711182 PMCID: PMC4159090 DOI: 10.1111/cyt.12071] [Citation(s) in RCA: 225] [Impact Index Per Article: 20.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/25/2013] [Indexed: 12/12/2022]
Abstract
OBJECTIVE A meta-analysis has not been previously performed to evaluate critically the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) of solely pancreatic ductal adenocarcinoma and address factors that have an impact on variability of accuracy. The aim of this study was to determine whether the presence of a cytopathologist, variability of the reference standard and other sources of heterogeneity significantly impacts diagnostic accuracy. METHODS We conducted a comprehensive search to identify studies, in which the pooled sensitivity, specificity, likelihood ratios for a positive or negative test (LR+, LR-) and summary receiver-operating curves (SROC) could be determined for EUS-FNA of the pancreas for ductal adenocarcinoma using clinical follow-up, and/or surgical biopsy or excision as the reference standard. RESULTS We included 34 distinct studies (3644 patients) in which EUS-FNA for a solid pancreatic mass was evaluated. The pooled sensitivity and specificity for EUS-FNA for pancreatic ductal adenocarcinoma was 88.6% [95% confidence interval (CI): 87.2-89.9] and 99.3% (95% CI: 98.7-99.7), respectively. The LR+ and LR- were 33.46 (95% CI: 20.76-53.91) and 0.11 (95% CI: 0.08-0.16), respectively. The meta-regression model showed rapid on-site evaluation (ROSE) (P = 0.001) remained a significant determinant of EUS-FNA accuracy after correcting for study population number and reference standard. CONCLUSION EUS-FNA is an effective modality for diagnosing pancreatic ductal adencarcinoma in solid pancreatic lesions, with an increased diagnostic accuracy when using on-site cytopathology evaluation.
Collapse
Affiliation(s)
- S Hébert-Magee
- Division of Anatomic Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35249-6823, USA.
| | | | | | | | | | | | | |
Collapse
|
104
|
Cizmeciyan MN, Kim JW, Bae S, Hong BH, Rotermund F, Sennaroglu A. Graphene mode-locked femtosecond Cr:ZnSe laser at 2500 nm. Opt Lett 2013; 38:341-343. [PMID: 23381431 DOI: 10.1364/ol.38.000341] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
We report, for the first time to our knowledge, femtosecond pulse generation from a graphene mode-locked Cr:ZnSe laser at 2500 nm. To minimize the insertion losses at the lasing wavelength, high-quality monolayer graphene transferred on a CaF(2) substrate was used in the experiments. Once mode-locking was initiated, the laser generated a stable train of 226 fs pulses with a time-bandwidth product of 0.39. The mode-locked laser operated at a pulse repetition rate of 77 MHz and produced 80 mW output power with an incident pump power of 1.6 W. To our knowledge, this is the longest laser wavelength at which graphene-based passive mode-locking has been demonstrated to date.
Collapse
Affiliation(s)
- M N Cizmeciyan
- Laser Research Laboratory, Department of Physics, Koç University, Istanbul, Turkey
| | | | | | | | | | | |
Collapse
|
105
|
Bae S, Kim YG, Choi J, Hong J, Lee S, Kang T, Jeon H, Hong K, Kim E, Kwak A, Lee CK, Yoo B, Park YB, Song EY, Kim S. Elevated interleukin-32 expression in granulomatosis with polyangiitis. Rheumatology (Oxford) 2012; 51:1979-88. [DOI: 10.1093/rheumatology/kes163] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
106
|
Voskoboynik M, Bae S, Ananda S, Desai J, Kosmider S, Gibbs P. An initial watch and wait approach is a valid strategy for selected patients with newly diagnosed metastatic colorectal cancer. Ann Oncol 2012; 23:2633-2637. [PMID: 22734008 DOI: 10.1093/annonc/mds184] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND A range of treatments are available for patients with metastatic colorectal cancer (mCRC). An initial period without active treatment, a 'watch and wait approach', is variably employed in routine practice; however, there is no data to support this approach. PATIENTS AND METHODS We prospectively collected data regarding clinician treatment recommendations for patients with newly diagnosed mCRC in addition to subsequent treatment and outcomes. Follow-up and management was according to standard protocols. RESULTS Seven hundred and thirty-six patients (59.1% male, 40.9% female) with mCRC (January 2003-December 2010) were analysed; the median age was 67.9 years (range 26.2-95.5). Three hundred and seventy-seven patients (51.2%) received immediate chemotherapy. For 133 (18.1%), treatment was considered inappropriate. 34 patients (4.6%) declined therapy. For 192 (26.1%), a watch and wait policy was adopted and 168 (87.5%) of these received treatment, at a median of 3.7 months (range 2-35 months) from diagnosis. Compared with patients immediately treated, the number receiving all active chemotherapy agents (30.4 versus 39.3%) was similar and median survival (27 versus 17 months, P = 0.0008) was superior. CONCLUSIONS Our study demonstrates that a substantial minority of patients underwent an initial watch and wait approach. Ultimately, they received a similar treatment exposure to patients treated immediately and the survival outcomes were not compromised.
Collapse
Affiliation(s)
- M Voskoboynik
- Department of Medical Oncology, Western Hospital, Footscray.
| | - S Bae
- Department of Medical Oncology, Western Hospital, Footscray
| | - S Ananda
- Department of Medical Oncology, Western Hospital, Footscray; Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Australia
| | - J Desai
- Department of Medical Oncology, Western Hospital, Footscray; Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Australia
| | - S Kosmider
- Department of Medical Oncology, Western Hospital, Footscray
| | - P Gibbs
- Department of Medical Oncology, Western Hospital, Footscray; Department of Medical Oncology, Royal Melbourne Hospital, Parkville, Australia
| |
Collapse
|
107
|
Ghrenassia E, Avouac J, Derk CT, Airo P, Khanna D, Ingegnoli F, Rosato E, Caramaschi P, Riccieri V, Bae S, Steen VD, Allanore Y, Irene A, De la Pena P, Sifuentes A, Marie I, Gourcerol G, Leroi AM, Menard JF, Ducrotte P. S.3.1 Watermelon stomach in SSc: a EUSTAR case-control study. Rheumatology (Oxford) 2012. [DOI: 10.1093/rheumatology/ker463] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
108
|
De Long SK, Li X, Bae S, Brown JC, Raskin L, Kinney KA, Kirisits MJ. Quantification of genes and gene transcripts for microbial perchlorate reduction in fixed-bed bioreactors. J Appl Microbiol 2012; 112:579-92. [PMID: 22188394 DOI: 10.1111/j.1365-2672.2011.05225.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIMS Optimization of full-scale, biological perchlorate treatment processes for drinking water would benefit from knowledge of the location and quantity of perchlorate-reducing bacteria (PRB) and expression of perchlorate-related genes in bioreactors. The aim of this study was to quantify perchlorate removal and perchlorate-related genes (pcrA and cld) and their transcripts in bioreactors and to determine whether these genes or transcripts could serve as useful biomarkers for perchlorate treatment processes. METHODS AND RESULTS Quantitative PCR (qPCR) assays targeting pcrA and cld were applied to two pilot-scale, fixed-bed bioreactors treating perchlorate-contaminated groundwater. pcrA and cld genes per microgram of DNA were two- to threefold higher and three- to fourfold higher, respectively, in the bioreactor showing superior perchlorate-removal performance. In a laboratory-scale bioreactor, quantities of pcrA and cld genes and transcripts were compared under two distinct performance conditions (c.60 and 20% perchlorate removal) for a 5-min empty bed contact time. cld genes per microgram of DNA were approximately threefold higher and cld transcripts per microgram of RNA were approximately sixfold higher under the higher perchlorate-removal condition. No differences in pcrA genes or transcripts per microgram of DNA or RNA, respectively, were detected between the c.60 and 20% perchlorate-removal conditions, possibly because these assays did not accurately quantify pcrA genes and transcripts in the mixed culture present. CONCLUSIONS Quantities of cld genes and transcripts per microgram of DNA and RNA, respectively, were found to be higher when perchlorate removal was higher. However, quantities of pcrA and cld genes or transcripts were not found to directly correlate with perchlorate-removal rates. SIGNIFICANCE AND IMPACT OF THE STUDY To our knowledge, this study represents the first application of qPCR assays to quantify perchlorate-related genes and transcripts in continuous-flow bioreactors. The results indicate that cld gene and transcript quantities can provide insights regarding the quantity, location and gene expression of PRB in bioreactors.
Collapse
Affiliation(s)
- S K De Long
- Department of Civil, Architectural, and Environmental Engineering, The University of Texas at Austin, Austin, TX, USA.
| | | | | | | | | | | | | |
Collapse
|
109
|
Yoon Y, Jung J, Lee B, Lee Y, Lee J, Kim H, Bae S, Nam M, Lee K, Yago J. First Report of Rice stripe virus of Proso Millet in Korea. Plant Dis 2012; 96:150. [PMID: 30731864 DOI: 10.1094/pdis-05-11-0453] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Rice stripe virus (RSV; genus Tenuivirus) is a serious threat to rice production in Korea (2). In 1965, a disease outbreak was observed on rice in South Korea, with plants showing yellow stripe symptoms (2). Reoccurrence of RSV in rice was observed again in 1980 in Gyeonggi and Chungcheong. In 2001, RSV was estimated to be infecting approximately 4,663 ha of rice in the provinces of Gyeonggi and Gangwha and approximately 5,000 ha of riceland in the provinces of Buan and, Seocheon (3). Proso millet (Panicum miliaceum L.) is grown as a cereal grain crop and used mainly for human food in South Korea (1). In June 2009, proso millet plants that displayed yellow stripe symptoms were collected at Sinjeon-Myeon, Gangjin-Gun, and Jeollanam-do provinces, where an outbreak of RSV in rice was reported. Diseased plants tested positive to RSV with an ELISA Kit (KisanBio, Seoul, Korea). Total RNA was extracted from leaf tissue with an RNeasy Plant Mini Kit (Qiagen Inc., Valencia, CA). RSV coat protein specific-primers were produced (5' TGTGGAACATAGTCCCACAGTAAGT 3'(upstream), 5' CTAAGCCGCAACCATTCCTCCAGT 3'(downstream). Reverse transcription-PCR confirmed the presence of a 494-bp product as predicted for the presence of RSV. The coat protein of RSV isolates collected from proso millet, rice, and foxtail millet in the same area was also sequenced. Results confirmed that phylogenetic relationships were of high homology: 98.9% between RSV isolates from rice and foxtail millet, 99.2% between isolates from rice (GenBank Accession No. JN245626) and proso millet (GenBank Accession No. JN245627); 99.6% between rice and foxtail millet (GenBank Accession No. JN245628); and 99.6% between foxtail millet and proso millet. In addition, sequence comparisons showed 96 to 99% identity with known RSV sequences available in GenBank (Accession No. X53563) (4). To our knowledge, this is the first report of RSV of proso millet in South Korea. The finding of this disease confirms further spread of the virus within the northern part of South Korea and the need for research to develop more effective management options to reduce the impact of RSV in proso millet. References: (1) Y. Y. Choi et al. Biosci. Biotechnol. Biochem. 69:31, 2005. (2) B. C. Lee et al. Res. Plant Dis. 10:30, 2004. (3) B. C. Lee et al. Res. Plant Dis. 14:210, 2008. (4) Y. Zhu. J. Gen. Virol. 72:763, 1991.
Collapse
Affiliation(s)
- Y Yoon
- Functional Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| | - J Jung
- Functional Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| | - B Lee
- Crop Environment Research Division, NICS, RDA, Suwon, 441-857, Korea
| | - Y Lee
- Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| | - J Lee
- Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| | - H Kim
- Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| | - S Bae
- Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| | - M Nam
- Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| | - K Lee
- Division of Applied Biology and Chemistry, Kyungpook National University, Daegu 702-701, Korea
| | - J Yago
- Functional Crop Resource Development Division, NICS, RDA, Miryang, 627-803, Korea
| |
Collapse
|
110
|
Yi J, An Y, Lee J, Kim M, Bae S. 1073 POSTER 17AAG Inhibits TGF-beta1-induced Cell Migration in MvlLu Cells. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70716-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
111
|
Mabasa L, Cho K, Bae S, Walsh DM, Asija P, Park CS. Lipotropes (methyl nutrients) inhibit growth of feline lymphoma in vitro. Res Vet Sci 2011; 93:259-63. [PMID: 21665236 DOI: 10.1016/j.rvsc.2011.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2010] [Revised: 03/16/2011] [Accepted: 05/18/2011] [Indexed: 10/18/2022]
Abstract
Feline lymphoma is one of the most frequently diagnosed tumors in cats. Lipotropes are dietary methyl donors that may modulate DNA methylation status and the expression of genes involved in growth and apoptosis of feline lymphoma cells. The specific objective of the study was to determine if lipotropes affect the growth of feline lymphoma cells, which entailed examining a correlation between lymphoma cell proliferation and apoptosis. F1B and FeLV-3281 cells were cultured and treated with 20 times the level of lipotropes contained in the basal culture medium. Cell growth and death and caspase 3 and tumor protein p53 activity were measured. Lipotropes were found to significantly reduce cell growth; increased cell death and caspase 3 and p53 activity was seen in F1B cells after 72 h, but the effect was minimal on FeLV-3281. These results could be useful in the development of dietary strategies for treating and preventing feline lymphoma.
Collapse
Affiliation(s)
- L Mabasa
- Department of Animal Sciences, North Dakota State University, Fargo, ND 58108, USA
| | | | | | | | | | | |
Collapse
|
112
|
Wen L, Bae S, Ahn W. Therapeutic effects of systemic PDT in a leukemia animal model using A20 cell lines. Photodiagnosis Photodyn Ther 2011. [DOI: 10.1016/j.pdpdt.2011.03.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
113
|
Battogtokh G, Chaturvedi P, Wen L, Bae S, Ahn W. Synthesis and characterization of chlorin based anticancer drug conjugate. Photodiagnosis Photodyn Ther 2011. [DOI: 10.1016/j.pdpdt.2011.03.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
114
|
Ansari S, Battogtokh G, Wen L, Bae S, Ahn W. Synthesis of chlorin-based fatty acid conjugate as photosensitizer for photodynamic therapy. Photodiagnosis Photodyn Ther 2011. [DOI: 10.1016/j.pdpdt.2011.03.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
115
|
Bae S, Asadi M, Millar JL, Jones I, McLaughlin S, Bui A, Steele M, Chao MW, English D, Gibbs P. An analysis of colorectal cancer (CRC) following a diagnosis of prostate cancer (CaP): Is it due to earlier diagnosis or increased incidence? J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
116
|
Kim RH, Lee RS, Williams D, Bae S, Woo J, Lieberman M, Oh JE, Dong Q, Shin KH, Kang MK, Park NH. Bisphosphonates induce senescence in normal human oral keratinocytes. J Dent Res 2011; 90:810-6. [PMID: 21427353 DOI: 10.1177/0022034511402995] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) commonly occurs in individuals receiving bisphosphonates (BPs) with clinical manifestations of the exposed necrotic bone. Although defective wound healing of soft tissue is frequently, if not always, observed in BRONJ, the effects of BPs on oral soft tissue or cells remain unknown. To investigate the effects of BPs on cells of oral mucosal tissue, we studied the effect of pamidronate (PAM), one of the BPs most commonly administered to cancer patients, on the phenotypes of normal human oral keratinocytes (NHOK) and fibroblasts (NHOF). When exposed to PAM at 10 µM, NHOK, not NHOF, underwent senescence: NHOK overexpressed senescence-associated β-galactosidase (SA-β-Gal), p16INK4A, IL-6, and IL-8. When exposed to a higher level (50 µM) of PAM, NHOK maintained senescent phenotypes, but NHOF underwent apoptosis. PAM-induced senescence in NHOK is mediated, in part, via geranylgeranylation of the mevalonate pathway. Our in vitro 3D oral mucosal tissue construction studies further demonstrated that PAM induced senescence and impaired re-epithelialization of oral mucosa. Analysis of these data indicates that premature senescence of oral mucosal cells and subsequent defective soft-tissue wound healing might be partly responsible for the development of BRONJ in individuals receiving PAM or other BPs.
Collapse
Affiliation(s)
- R H Kim
- UCLA School of Dentistry, Center for the Health Sciences, Room 43-091, 10833 Le Conte Ave, Los Angeles, CA 90095, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
117
|
Ryoo H, Bae S, Kim M, Lee KH, Song H, Chae Y, Lee W, Baek J. Phase II study of fixed-dose-rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced bile duct cancer: Daegu Gyeoungbuk Oncology Group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
280 Background: This phase II study evaluated efficacy of fixed dose rate (FDR) infusion of gemcitabine (10mg/m2/min) and UFT combination in chemo-naïve patients with advanced bile duct cancer. Methods: This was an open-label, single-arm, multicenter, phase II study with a Simon two-stage minimax design. Patients received the FDR gemcitabine 1,000mg/m2 for 3 consecutive weeks and UFT 400 mg/m2 on days 1-21. The cycle was repeated every 28 days. The primary end point was Response Evaluation Criteria in Solid Tumors (RECIST) -defined objective response rate. Secondary end points included clinical benefit response (CBR), safety, progression-free survival (PFS), and overall survival (OS). Clinical characteristics including four single nucleotide polymorphisms in DNA repair genes (RecQ1, RAD54L, XRCC1, ATM) were evaluated whether these influence the overall survival. Results: Between December 2006 and February 2008, fifty-one patients were enrolled, with a median age of 58 years. The majority of patients (76%) had intra-hepatic disease. Fourteen patients (27%) had a RECIST investigator-assessed, partial response (PR); disease control rate (PR + stable disease) was 55%. CBR was 14% among 37 evaluable patients. Hematologic toxicity was main grade 3 or 4 treatment-related adverse events. Median PFS was 4.0 months (95% CI, 2.9 to 5.1 months). Median OS was 7.0 months (95% CI, 3.5 to 10.5 months). Intrahepatic disease, poor performance, and, XRCC1 R194W C/C type were predictive markers of poor overall survival. Conclusions: FDR gemcitabine and UFT demonstrated apparent activity in patients with advanced bile duct cancer. However, this activity did not translate to prolong survival. The location of disease, performance status, and, polymorphic variants of DNA repair genes may affect clinical outcome of patients with advanced bile duct cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Ryoo
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| | - S. Bae
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| | - M. Kim
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| | - K. H. Lee
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| | - H. Song
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| | - Y. Chae
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| | - W. Lee
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| | - J. Baek
- Daegu Catholic University Hospital, Daegu, South Korea; Daegu Catholic University College of Medicine, Daegu, South Korea; Yeungnam University Hospital, Daegu, South Korea; Dongsan Medical Center, Keimyung University, Daegu, South Korea; Kyungpook National University Hospital, Daegu, South Korea; Daegu Fatima Hospital, Daegu, South Korea; Ulsan University Hospital, Ulsan, South Korea
| |
Collapse
|
118
|
Abstract
446 Background: Angiogenic factorCysteine-rich 61 (Cyr61) is a member of the CCN protein family that has been implicated in diverse biological processes such as cell adhesion, proliferation, angiogenesis, and tumorigenesis. An altered expression of Cyr61 is found to be associated with several human cancers. However, the correlation of expression of Cyr61 protein and clinical features of colorectal cancer remains unknown. Methods: Cyr61 expression in colorectal cancer and normal tissues was evaluated by Western blot analysis. Immunohistochemical staining was carried out using tissue microassay (TMA) to examine the expression status of Cyr61. Correlations of Cyr61 over-expression with various clinicopathologic factors were also determined. Statistical analysis was performed to explore the links between expression of the Cyr61 and clinicopathological parameters. Results: On Western blot analysis Cyr61 up-regulation was observed in colorectal cancer tissues (17/21, 80.9%). In 234 colorectal cancers, tumor tissue microarray revealed significantly up-regulated Cyr61 protein expression in colorectal cancer tissues versus normal tissues adjacent to tumor. Cyr61 expression was high in 136 of 234 cases of colorectal carcinomas (58.1%). Cyr61 over-expression was significantly associated with TNM stage (p=0.012) and regional lymph node involvement (p=0.018). Kaplan-Meier survival analysis showed that over-expression of Cyr61 was related to poor survival of colorectal cancer patients (p=0.031). But significant associations were not found between CYR61 expression versus tumor grade, age and gender. Conclusions: Our results suggest that Cyr61 is highly expressed in colorectal carcinomas and Cyr61 may play a role in the progression of colorectal cancers. Also, Cyr61 might be a new molecular marker to predict the prognosis and serve as valuable targets for therapeutic intervention of patients with colorectal carcinoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Baek
- Department of Surgery, Soonchunhyang University, Cheonan, South Korea; Department of Internal Medicine, Soonchunhyang University, Cheonan, South Korea; Department of Pathology, Soonchunhyang University, Cheonan, South Korea
| | - S. Bae
- Department of Surgery, Soonchunhyang University, Cheonan, South Korea; Department of Internal Medicine, Soonchunhyang University, Cheonan, South Korea; Department of Pathology, Soonchunhyang University, Cheonan, South Korea
| | - D. Jeong
- Department of Surgery, Soonchunhyang University, Cheonan, South Korea; Department of Internal Medicine, Soonchunhyang University, Cheonan, South Korea; Department of Pathology, Soonchunhyang University, Cheonan, South Korea
| |
Collapse
|
119
|
Lim S, Lee K, Joo Y, Lee W, Yoon S, Sohn S, Bae S, Hyun M, Kim H, Eom H. The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.6563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
120
|
|
121
|
Bae S, Baek M, Jeong D, Kim C, Kim E, Shin E, Park D. Expression changes of angiogenic factors in rectal carcinomas after neoadjuvant chemoradiotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
122
|
Chung Y, Kim B, Chen C, Wang J, CHU H, Yoon J, Seetalarom K, Bae S, Chao Y, Li C, Lee T. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
123
|
Lee S, Kim H, Kim S, Kim C, Bae S, Lee K, Yun J, Hong D, Park H. Preliminary phase II results of oxaliplatin, 5-FU, and leucovorin in advanced biliary tract cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
124
|
Park H, Kim H, Kwon J, Yun J, Lee S, Bae S, Kim C, Lee N, Hong D. Pathophysiological role of hormones and cytokines in cancer cachexia. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
125
|
Kim H, Yun J, Kim K, Kim S, Lee S, Bae S, Lee K, Hong D, Park H. Oxaliplatin, 5-fluorouracil, and folinic acid as first-line treatment in metastatic or recurrent gastric cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
126
|
Lee K, Kim M, Hyun M, Song H, Kim J, Park K, Lee W, Cho Y, Bae S, Ryoo H. Cancer pain management with hydromorphone OROS in Korean cancer patients: Evaluation of its clinical usefulness in reduction of breakthrough pain medication frequency: Multicenter, prospective, open-label study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
127
|
Bae S, Ryoo H, Kim M, Lee KH, Kim J, Do Y, Song H, Chae Y, Lee W, Baek J. Phase II study of fixed dose-rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced bile duct cancer: Daegu Gyeoungbuk Oncology Group. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
128
|
Chae Y, Kim J, Sohn S, Kang B, Ryoo H, Bae S, Choi G, Baek J, Kim Y, Cho Y. Association of MGMT-535G>T polymorphism with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e14067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
129
|
Bae S, Kim JE, Hwang J, Lee YS, Lee HH, Lee J, Lyoo IK, Renshaw PF, Yoon SJ. Increased prevalence of white matter hyperintensities in patients with panic disorder. J Psychopharmacol 2010; 24:717-23. [PMID: 18957476 DOI: 10.1177/0269881108098476] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of the current study is to compare the prevalence, severity and location of cerebral white matter hyperintensities (WMH) between patients with panic disorder (PD) and healthy control subjects. Patients with PD (n = 24) and matched healthy control subjects (n = 24) were scanned using a 3.0 Tesla whole-body magnetic resonance scanner. Axial T2-weighted and fluid-attenuated inversion recovery images were acquired and evaluated for the prevalence, severity and location of WMH using the modified composite scale of Fazekas and Coffey and coded separately for deep and periventricular WMH. Logistic regression analyses were used to assess the association between WMH and the diagnosis of PD. A greater severity of total WMH was associated with a diagnosis of PD in a dose-dependent pattern (odds ratio [OR] = 8.8, P = 0.005 for mild WMH; OR = 27.7, P = 0.007 for moderate to severe WMH). Deep WMH, where most group differences originated, were predominantly located in the frontal region of the brain (n = 16 in PD, n = 1 in control). The current report is the first study to report an increased prevalence of WMH in patients with PD.
Collapse
Affiliation(s)
- S Bae
- Department of Psychiatry, Seoul National University and Hospital, Seoul, South Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
130
|
Tomitaka A, Kobayashi H, Yamada T, Jeun M, Bae S, Takemura Y. Magnetization and self-heating temperature of NiFe2O4nanoparticles measured by applying ac magnetic field. ACTA ACUST UNITED AC 2010. [DOI: 10.1088/1742-6596/200/12/122010] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
131
|
Shim A, Crider D, McDaniel L, Bae S. Comparison of stability scores on college aged students using commercial balance programs. J Sci Med Sport 2010. [DOI: 10.1016/j.jsams.2009.10.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
132
|
Bae S, Lee K, Kim J. P981 CIZAR induces apoptosis on cervical carcinoma cells by p53/Rb-dependent and -independent pathway. Int J Gynaecol Obstet 2009. [DOI: 10.1016/s0020-7292(09)62468-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
133
|
Bae S, Park H, Ahn Y, Lim D, Shim Y, Kim J, Kim K, Choi Y, Park K. 9106 The role of involved field radiotherapy as a salvage treatment for loco-regional recurrence after complete resection of NSCLC (non-small cell lung cancer). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71819-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
134
|
Song H, Park K, Do Y, Kim J, Lee K, Bae S, Ryoo H, Baek J, Lee W, Jung H. 3062 The cancer pain survey, 2006 in Daegu, Korea. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70661-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
135
|
Park S, Kim C, Kim H, Hong D, Lee S, Won J, Park H, Bae S, Lee Y, Kim E, Jung Y. The usefulness of interphase fluorescence in situ hybridization at diagnosis of myeloma in addition to metaphase cytogenetics. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19558 Background: Multiple myeloma is characterized by the accumulation of malignant plasma cells within the bone marrow and regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. The clinical heterogeneity of myeloma is dictated by the cytogenetic aberrations present in the clonal plasma cells. Fluorescence in situ hybridization (FISH) overcomes the limitations of standard cytogenetics and allows for the detection of numerical and structural chromosomal abnormalities in both metaphase spreads and interphase nuclei. Methods: We evaluated the chromosome abnormalities in 34 MM patients using conventional cytogenetics and interphase FISH with 6 probes such as IGH/CCND1, IGH/FGFR3, IGH/MAF, DS13S319/LAMP1, IGH/BAP, and p53/CEP17. Results: Cytogenetic abnormalities were found in 24 (70.6%) of the 28 MM patients. 10 (35.7%) patients had abnormal metaphases by conventional cytogenetics. Interphase FISH results were abnormal in 21 (61.8%) patients and 11 (52.3%) patients had abnormal interphase FISH but normal metaphases. The evidence of the loss of D13S319 with or without loss of LAMP1 was found in 6 (21.4%) patients, and loss of p53±CEP17 for 2 patients, IGH-BAP for 9 (26.5%) patients, IGH/FGFR3 for 2 patients, and IGH/CCND1 for 7 (20.6%) patients, respectively. However, there were none positive for IGH/MAF. Chromosome 13 abnormalities and IGH rearrangement is correlated with poor clinical outcome. Conclusions: Interphase FISH can provide useful information to evaluate the presence of prognostic chromosome abnormalities in addition to metaphase cytogenetics. And it should be used in the routine evaluation of multiple myeloma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Park
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - C. Kim
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - H. Kim
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - D. Hong
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - S. Lee
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - J. Won
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - H. Park
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - S. Bae
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - Y. Lee
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - E. Kim
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| | - Y. Jung
- Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea; Soonchunhyang University Hospital, Seoul, Republic of Korea; Soonchunhyang Chunan Hospital, Chunan, Chungnam, Republic of Korea
| |
Collapse
|
136
|
Lee S, Ryoo H, Bae S, Song H, Kim M, Lee K, Lee W, Park K, Kim J, Baek J. Fixed dose rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced biliary cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15581 Background: Biliary cancer is diagnosed at advanced stage and recurrence is common after surgical resection. Gemcitabine and UFT combination chemotherapy showed promising results in advanced pancreatic cancer(APC) and fixed dose- rate(FDR) infusion(10mg/m2/min) of gemcitabine is more effective than 30min-infusion in APC patients. We conducted a prospective multicenter phase II study to evaluate the efficacy and toxicity of FDR gemcitabine and UFT combination chemotherapy in advanced biliary cancer(ABC) patients. We evaluated the quality of life(QOL) and relationship between treatment outcome and polymorphisms of DNA repair gene such as RecQ1, RAD54L, XRCC1 and ATM. Methods: We included the chemo-naive patients with measurable metastatic or recurrent biliary adenocarcinoma except gall bladder cancer. Patients received gemcitabine infusion of rate of 10mg/m2/min on day 1, 8, and 15 plus oral UFT (400mg/m2) on day 1 to 21. We used modified PCR-RFLP method to evaluate the polymorphism of DNA repair gene. The primary endpoint was response rate. Results: From October 2006 to March 2008, 47 patients were enrolled and 33 of them were included in this analysis. Median age was 58 years(range 33–73 years) and 18 patients were male. Partial response was 24.2% and disease control rate was 51.5%. The estimated median time to progression(TTP) was 87 days(95% CI 51–123). Median overall survival was 243 days(95% CI 114–372). Grade 3/4 neutropenia was observed in 12 of 33 patients(36.4%) and 17 times of 114 cycles of chemotherapy(14.9%). No febrile neutropenia was observed. Grade 3/4 thrombocytopenia occurred in 5 patients(15.2%). Non-hematologic toxicities were mild. Polymorphism of XRCC1 was related to TTP(TTP of wild, heterozygous variant and homozygous variant type was 162, 71 and 25 days, respectively. p=0.0039). QOL as a secondary endpoint was not analyzed at this time. Conclusions: FDR infusion of gemcitabine and UFT combination chemotherapy in chemo-naïve patients with ABC is a well-tolerated and effective regimen. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Lee
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - H. Ryoo
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - S. Bae
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - H. Song
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - M. Kim
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - K. Lee
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - W. Lee
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - K. Park
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - J. Kim
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| | - J. Baek
- Daegu Gyeongbuk Oncology Group; Daegu Catholic University Medical Center, Daegu, Republic of Korea; Keimyung University Hospital, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea; Dongguk University Hospital, Gyeungju, Republic of Korea; Kyungpook National University Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Daegu Gyeongbuk Oncology Group
| |
Collapse
|
137
|
Kim J, Song H, Do Y, Kim M, Lee K, Bae S, Ryoo H, Park K, Baek J, Lee W. A multicenter phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15520] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
138
|
Chae Y, Kim J, Sohn S, Moon J, Kim S, Ryoo H, Bae S, Choi G, Jun S, Lee M. Prognostic impact of apoptosis-related and DNA repair gene polymorphisms in patients with advanced colorectal cancer treated with capecitabine and oxaliplatin chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
139
|
Kang K, Choi B, Jang H, Kang Y, Jang J, Chai G, Bae S, Yoon S, Choi I. Fractionated stereotactic radiosurgery for primary hepatocellular carcinoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15669] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
140
|
Kim H, Lee S, Bae S, Kim C, Lee N, Lee K, Park S, Won J, Hong D, Park H. Phase II study of gemcitabine and oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
141
|
Lee H, Ahn M, Ahn J, Kwon J, Lee S, Bae S, Kim B, Kim H, Hong D, Park K. Pemetrexed monotherapy in patients with advanced non-small cell lung cancer who have had prior chemotherapy: A prospective phase II trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
142
|
Tavares de Melo R, Lukose T, Bae S, Kubin C, Lederer D, Arcasoy S, Wilt J, Sonett J, D’Ovidio F, Kawut S. 54: The Effect of CMV-Immune Globulin on Outcomes in CMV-Mismatched Lung Transplant Recipients. J Heart Lung Transplant 2008. [DOI: 10.1016/j.healun.2007.11.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
143
|
Urowitz MB, Gladman D, Ibañez D, Fortin P, Sanchez-Guerrero J, Bae S, Clarke A, Bernatsky S, Gordon C, Hanly J, Wallace D, Isenberg D, Ginzler E, Merrill J, Alarcón GS, Steinsson K, Petri M, Dooley MA, Bruce I, Manzi S, Khamashta M, Ramsey-Goldman R, Zoma A, Sturfelt G, Nived O, Maddison P, Font J, van Vollenhoven R, Aranow C, Kalunian K, Stoll T. Accumulation of coronary artery disease risk factors over three years: Data from an international inception cohort. ACTA ACUST UNITED AC 2008; 59:176-80. [DOI: 10.1002/art.23353] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
144
|
Murota H, Bae S, Hamasaki Y, Maruyama R, Katayama I. Emedastine difumarate inhibits histamine-induced collagen synthesis in dermal fibroblasts. J Investig Allergol Clin Immunol 2008; 18:245-252. [PMID: 18714531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
BACKGROUND Mast cell-derived histamine is known to act on dermal fibroblasts and contribute to formation of an intractable chronic allergic dermatitis. Although this fibrotic event may also occur in other organs such as the nasal mucosa, no direct evidence has been reported as to whether responsiveness to histamine by fibroblasts derived from different organs is of the same intensity. Furthermore, while type 1 histamine receptor (H1R) blockers have been shown to be effective for alleviation of the symptoms of allergic diseases, their ability to affect histamine-induced tissue remodeling has not yet been clarified. OBJECTIVE Our aim was to study the effect of H1R-blockers on histamine-induced tissue remodeling. METHODS A macroarray assay was used for a comprehensive analysis of histamine-induced gene expression by normal human fibroblasts. Fibroblasts derived from skin or nasal mucosa were cultured in the presence of various concentrations of histamine, and the synthesis of type 1 collagen was measured by means of semi-quantitative reverse-transcriptase polymerase chain reaction and enzyme-linked immunosorbent assay. To determine the effect of H1R blockers, diphenhydramine hydrochloride and emedastine difumarate were investigated in this assay. RESULTS Histamine induced expression of various kinds of fibrogenic molecules in fibroblasts. Increased type 1 collagen expression was observed in fibroblasts treated with high-dose (0.1 mM to 1 microM) and low-dose (1 pM) histamine. This histamine-induced type 1 collagen synthesis was effectively diminished by emedastine difumarate. While organ specificity seems to be involved, emedastine difumarate is considered to be an effective drug for reversal of such histamine-induced remodeling in the skin. CONCLUSIONS We found that the expression of fibroblast-derived genes is differentially regulated by different concentrations of histamine and that the robustness of the inhibitory action of H1R blockers is different for skin-derived and nasal mucosa-derived fibroblasts. We believe that our findings may contribute to a better understanding of the mechanisms of histamine-induced tissue remodeling and provide information useful for the management of refractory allergic dermatitis.
Collapse
Affiliation(s)
- H Murota
- Department of Dermatology, Course of Integrated Medicine, Osaka University School of Medicine, Osaka, Japan.
| | | | | | | | | |
Collapse
|
145
|
Slifstein M, Kegeles L, Xu X, Hackett E, Castrillon J, Bae S, Laruelle M, Abi-Dargham A. Amphetamine challenge with [18F]fallypride: Striatal and extrastriatal measurements in healthy human volunteers. Neuroimage 2008. [DOI: 10.1016/j.neuroimage.2008.04.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
146
|
Lee YJ, Lee HJ, Lee JS, Jeoung D, Kang CM, Bae S, Lee SJ, Kwon SH, Kang D, Lee YS. A novel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20. Oncogene 2007; 27:2999-3009. [PMID: 18059335 DOI: 10.1038/sj.onc.1210966] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Although heat-shock factor (HSF) 1 is a known transcriptional factor of heat-shock proteins, other pathways like production of aneuploidy and increased protein stability of cyclin B1 have been proposed. In the present study, the regulatory domain of HSF1 (amino-acid sequence 212-380) was found to interact directly with the amino-acid sequence 106-171 of Cdc20. The association between HSF1 and Cdc20 inhibited the interaction between Cdc27 and Cdc20, the phosphorylation of Cdc27 and the ubiquitination activity of anaphase-promoting complex (APC). The overexpression of HSF1 inhibited mitotic exit and the degradations of cyclin B1 and securin, which resulted in production of aneuploidy and multinucleated cells, but regulatory domain-deficient HSF1 did not. Moreover, HSF1-overexpressing cells showed elevated levels of micronuclei and genomic alteration. The depletion of HSF1 from cells highly expressing HSF1 reduced nocodazole-mediated aneuploidy in cells. These findings suggest a novel function of HSF1 frequently overexpressed in cancer cells, to inhibit APC/C activity by interacting with Cdc20, and to result in aneuploidy development and genomic instability.
Collapse
Affiliation(s)
- Y J Lee
- Division of Radiation Effect, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
147
|
Kay C, Jang J, Bae S, Kim Y, Choi J, Yoon S, Oh S, Choi I. Clinical Experience of Simultaneous Multitarget Irradiation Using Tomotherapy in Pulmonary Metastasis. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
148
|
Kim H, Lee S, Bae S, Kim C, Lee N, Lee K, Park S, Won J, Hong D, Park H. 3559 POSTER A phase II study of gemcitabine in combination with oxaliplatin as first line chemotherapy in patients with inoperable biliary tract adenocarcinoma. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71062-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
149
|
Lee Y, Cho B, Choi H, Sohn J, Kang S, Kim S, Bae S, Ryoo H, Kim J. Impact of second hand smoke (SHS) exposure on the likelihood of mutations in epidermal growth factor receptor (EGFR) gene in patients with non-small cell lung cancer (NSCLC) who had never smoked. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7633 Background: The presence of EGFR mutations in NSCLC has strongly associated with never-smoking history. SHS exposure is associated with higher risk of lung cancer. We have conducted this study to evaluate the association between SHS exposure and likelihood of mutations in EGFR gene in NSCLC patients who had never smoked. Methods: SHS exposure information from a total of 93 never smokers (<100 lifetime cigarettes) with newly diagnosed primary NSCLC was obtained using a standardized questionnaire. Patients were asked whether they were regularly exposed to SHS at home or work places, respectively. Nucleotide sequencing of the kinase domain of EGFR (exons 18 to 21) was performed using nested PCR amplification of individual exons. Results: Patient characteristics (n=93) included median age 57 years; female (n= 81); adenocarcinoma ± bronchoalveolar carcinoma (n= 82); EGFR mutation (1 mutation in exon 18 G719, 31 in-frame deletions in exon 19, 10 mutations in codon 858 in exon 21). Fifty-two (55.9%) of the patients reported having been exposed to SHS, including 46 (49.5%) exposed at home and 13 (14.0%) exposed at work. The incidence of EGFR mutations was not associated with female gender and adenocarcinoma histology. Patients with SHS exposure showed a trend towards lower incidence of EGFR mutations (36.5% vs. 56.1%, P= 0.060) and a significantly lower incidence of deletion mutations in exon 19 (57.9% vs. 87.0%, P= 0.033). When the incidence of EGFR mutations was compared, no difference between SHS exposure at home and work places was found. No significant differences were found for other clinicopathological factors according to SHS exposure. Conclusions: Our results indicate weak evidence of relationship between likelihood of mutation in EGFR gene and SHS exposure. The deletion mutations in exon 19 were significantly less common in patients with SHS exposure. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Lee
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - B. Cho
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - H. Choi
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - J. Sohn
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - S. Kang
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - S. Kim
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - S. Bae
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - H. Ryoo
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| | - J. Kim
- Yonsei Cancer Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Daegu Catholic University Hospital, Daegu, Republic of Korea
| |
Collapse
|
150
|
Kim J, Song H, Do Y, Lee K, Kim M, Ryu H, Bae S, Park G, Baek J, Lee W. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15026 Background: The present study was conducted to evaluate the efficacy and safety of a combination regimen of docetaxel plus oxaliplatin in patients with advanced gastric cancer. Methods: Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous docetaxel 65 mg/m2 plus oxaliplatin (Oxalpla®, Yuhan.Co. Seoul, Korea) 120 mg/m2 on days 1 in a 3-week cycle. Treatment was continued until disease progression, patient refusal, or an unacceptable toxicity up to 9 cycles. Results: Forty-two patients were enrolled in the current study. Of these, 39 were assessable for efficacy and 41 assessable for toxicity. Seventeen partial responses were confirmed, giving an overall response rate of 40.5% (95% CI: 26.0% to 54.1%, intention-to-treat analysis). At a median follow-up of 160.5 days, the median time to progression was 6.1 months, whereas median overall survival was not reached yet. Grade 3/4 neutropenia occurred in 10 patients, plus febrile neutropenia was observed in 3 patients. Most common non-hamatologic toxicity was nausea (grade 1/2 56.9%). There were two treatment-related deaths. Conclusions: Docetaxel and oxaliplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Kim
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - H. Song
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - Y. Do
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - K. Lee
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - M. Kim
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - H. Ryu
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - S. Bae
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - G. Park
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - J. Baek
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| | - W. Lee
- Kyungpook Natl University Hospital, Daegu, Republic of Korea; Dongsan Medical Center, Daegu, Republic of Korea; Yeungnam University Hospital, Daegu, Republic of Korea; Daegu Catholic Universitiy Medical Center, Daegu, Republic of Korea; Dongguk University Gyongju Hospital, Gyungju, Republic of Korea; Daegu Fatima Hospital, Daegu, Republic of Korea
| |
Collapse
|